Assesses all-oral treatments in acute myeloid leukemia, indicating a potential effective alternative to chemotherapy.
According to two phase I/II trials, ASCERTAIN-V and SAVE, the all-oral regimen of decitabine-cedazuridine and venetoclax, with revumenib added in the latter study, could be an effective option for patients with acute myeloid leukemia who would otherwise receive intravenous or subcutaneous chemotherapy.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: